CD8A and neoplasm: Immune landscape in the tumor was determined by flow cytometry, and the results showed that the proportion of CD8+ T cells was increased in terbinafine-treated mice (, figure 5D and online supplemental figure 5B), coinciding with our previous in vitro findings.